– Regulatory Filing: Gilead Sciences plans to file for regulatory approval based on the PURPOSE 1 and 2 trial results.
– Global Access: The company aims to make lenacapavir accessible in high-incidence, resource-limited countries.
Lenacapavir’s approval could mark a significant milestone in HIV prevention, offering a convenient and effective solution for individuals at risk of infection
